Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19896479 | 0.98 | MAPT (0.52) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| Aniline SCHEMBL22169182 | 0.92 | MAPT (0.47) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| SCHEMBL540557 | 0.86 | MAPT (0.54) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| SCHEMBL17879577 | 0.82 | MAPT (0.50) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| SCHEMBL30548758 | 0.82 | MAP2K7 (0.41) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| SCHEMBL11375178 | 0.80 | MAPT (0.48) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| SCHEMBL11385640 | 0.79 | MAPT (0.46) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| SCHEMBL22085893 | 0.79 | ALDH1A1 (0.38) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| SCHEMBL11099046 | 0.79 | MAPT (0.46) | MAPTKMT2ANPSR1MEN1APOBEC3G | |
| SCHEMBL11177994 | 0.77 | MAPT (0.45) | MAPTKMT2ANPSR1MEN1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017041771-A1 | PROCESS FOR THE PREPARATION OF CERITINIB USING \"IN SITU\" PREPARED 5-METHYL-2-(1 -METHYLETHOXY)-4-(4-PIPERIDINYL)-BENZENAMINE MONOHYDROCHLORIDE (1 :1 ) AS AN INTERMEDIATE | ZENTIVA, K.S. (CZ) | 2017-03-16 | — | — | WO | claimed |
| CN-116284001-A | DCLK1 inhibitor, preparation method, pharmaceutical composition and application | 中国药科大学 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022214008-A1 | HIGHLY ACTIVE HPK1 KINASE INHIBITOR | 杭州阿诺生物医药科技有限公司 | 2022-10-13 | — | — | WO | disclosed |
| EP-2985284-B1 | DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVES | TREAMID THERAPEUTICS GMBH (DE) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021057867-A1 | CLASS OF CDK INHIBITOR BASED ON ORGANIC ARSINE, PREPARATION METHOD AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2021-04-01 | — | — | WO | disclosed |
| EP-3265455-B1 | PROCESS FOR PREPARING CERITINIB AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2020-07-15 | — | — | EP | disclosed |
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20200039935-A1 | Chemical Process for Preparing Pyrimidine Derivatives and Intermediates Thereof | SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD (CN) | 2020-02-06 | — | — | US | disclosed |
| WO-2019149128-A1 | 5-CHLORO-2,4-PYRIMIDINE DERIVATIVE USED AS ANTI-TUMOR DRUG | 陆柯潮 | 2019-08-08 | — | — | WO | disclosed |
| EP-2990405-B1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-4818277-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0306222-A2 | Benzenesulfonanilide derivatives and fungicides for agriculture and horticulture | HOKKO CHEMICAL INDUSTRY CO., LTD (JP) | 1989-03-08 | — | — | EP | disclosed |
| EP-0035893-B1 | HERBICIDAL BENZENE- AND PYRIDINE-SULFONAMIDE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4303673-A | N-Propionylsarcosineanilides, process for their preparation, and pharmaceutical compositions containing them | A. NATTERMANN & CIE. GMBH (DE) | 1981-12-01 | — | — | US | disclosed |
| EP-0035893-A2 | Herbicidal benzene- and pyridine-sulfonamide derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-09-16 | — | — | EP | disclosed |
| US-4239688-A | Herbicidal N-(haloacetyl)-N-(N'-methylenepyrrolidonyl-2-mercaptoalkylanilines | GAF CORPORATION (US) | 1980-12-16 | — | — | US | disclosed |
| US-4203901-A | Process for making N-(N'-methylenepyrrolidonyl)-2-substituted anilines | GAF CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-4202821-A | N-(N'-Methylenepyrrolidonyl)-2-substituted anilines | GAF CORPORATION (US) | 1980-05-13 | — | — | US | disclosed |
| US-4146688-A | CHAIN EXTENSION | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-27 | — | — | US | disclosed |
| US-3985894-A | Method of controlling rice blast with N-(alkylthiophenyl)maleimides | THE DOW CHEMICAL COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | DCK, DPYD, BRAF | MAPT 1055/4885KMT2A 1408/4885NPSR1 4580/4885 |
| US-20200039935-A1 | Chemical Process for Preparing Pyrimidine Derivatives and Intermediates Thereof | PDXK, DCK, DPYD | MAPT 3373/4885KMT2A 1186/4885NPSR1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.